Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a ...

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company's launch and $100 million in initial financing, including seed financing and ...

Citi analyst David Lebowitz initiated coverage with a Buy rating on Celldex (CLDX – Research Report) today and set a price target of ...

As the United States stock market reaches new heights, buoyed by a robust jobs report and record highs in major indices like ...

Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply ...

Global Lipid Nanoparticles Market was valued at US$ 820.51 million in 2023 and is projected to hit the market valuation of US$ 2,387.98 million by 2032 at a CAGR of 12.6% during the forecast period ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The terrorists took the lives of some Israelis with special needs, and these losses, along with the trauma and dislocations of the war, have caused great suffering in this community. Sen. Lindsey ...